Metastatic Merkel Cell Carcinoma: Insights on the Clinical Application of Immune Checkpoint Inhibitors

Download All
This multifaceted program, which includes a module, interactive toxicity management algorithm tool, summary resource guide, and expert commentaries, equips clinicians with evidence-based insights on how to incorporate immune checkpoint inhibitors into clinical management of patients with metastatic Merkel cell carcinoma.

Summary Resource

In this downloadable resource, expert faculty Paul Nghiem, MD reviews the rationale for and key data supporting the use of immune checkpoint inhibitors in the treatment of MCC. For additional in-depth analysis, please review the accompanying CME-certified text module, downloadable slides, and ClinicalThought commentaries, as well as our interactive algorithm tool for expert guidance with managing immune-related adverse events.

Released: March 6, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

This activity is supported by an educational grant from
Pfizer Inc.
Merck KGaA

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.